Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients
Salem, H., Morcos, N., Doss, W., Makhlouf, M., El Atrebi, K., Saleh, E. (2022). Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients. EKB Journal Management System, 60(1), 73-84. doi: 10.21608/ejaps.2022.125337.1026
Hiam Salem; Nadia Y. S. Morcos; Wahid Doss; Mohamed Makhlouf; Kamal El Atrebi; Eman Saleh. "Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients". EKB Journal Management System, 60, 1, 2022, 73-84. doi: 10.21608/ejaps.2022.125337.1026
Salem, H., Morcos, N., Doss, W., Makhlouf, M., El Atrebi, K., Saleh, E. (2022). 'Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients', EKB Journal Management System, 60(1), pp. 73-84. doi: 10.21608/ejaps.2022.125337.1026
Salem, H., Morcos, N., Doss, W., Makhlouf, M., El Atrebi, K., Saleh, E. Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients. EKB Journal Management System, 2022; 60(1): 73-84. doi: 10.21608/ejaps.2022.125337.1026

Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients

Egyptian Journal of Pure and Applied Science
Article 5, Volume 60, Issue 1, January 2022, Page 73-84  XML PDF (746.1 K)
Document Type: Original Article
DOI: 10.21608/ejaps.2022.125337.1026
View on SCiNiTO View on SCiNiTO
Authors
Hiam Salem email 1; Nadia Y. S. Morcos1; Wahid Doss2; Mohamed Makhlouf3; Kamal El Atrebi4; Eman Saleh1
1Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
2Tropical Medicine and Hepatology Department, Faculty of Medicine, Cairo university, Giza, Egypt
3Internal Medicine Department, Faculty of Medicine, Ain shams university, Cairo, Egypt
4National Hepatology and Tropical Medicine Research Institute, Egypt
Abstract
Even though Sofosbuvir (SOF) has revolutionized the treatment of chronicHCV infection, treatment with pegylated interferon in combination with Ribavirin isconsidered the standard of care for treatment in many countries. Aim: This study aimedto monitor the efficacy and safety of SOF/RBV with or without Peg-INF-α-2a, inEgyptian patients with chronic HCV genotype 4. Subjects: 165 patients infected withHCV-GT4 were enrolled in this prospective study. Eligible patients received therecommended doses of SOF/RBV for 24 weeks (Dual treatment) or SOF/RBV/Peg-IFN-α-2a for 12 weeks (Triple treatment). All patients were followed up for 24 weeks afterthe end of therapy. Results: The highest SVR24 rates were attained with the Triple groupcorresponding to the Dual group. Patients who failed to treatment, had higher baselinePDGF in both groups, TNF-α in the Dual group, and lower TSH in the Triple group.Adverse effects included a decrease in hemoglobin and WBCs with an increase increatinine, ferritin and TSH. The favorable effects included normalization of liverindices, correction of hypolipidemia, together with a decrease in TNF-α. Moreover, thecurrent study showed the overall frequency of IL28B genotypes was 100% for genotypeCT. Results: Results of SOF-based therapies achieved better SVR24 rates with theaddition of Peg-INF-α-2a.
Keywords
HCV; Sofosbuvir; Interferon; Ribavirin; SVR
Statistics
Article View: 169
PDF Download: 124